Tag: Surgical hemostasis

According to a 2024 review published in the National Institutes of Health, traumatic hemorrhage is the leading preventable cause of death globally, underscoring the critical need for effective hemostatic agents. These agents, designed to promote blood clotting, vary significantly in their application methods, which is crucial for medical professionals to understand when determining **how are hemostatic agents given** in a specific situation.

Medically, anti-bleeding drugs are most accurately known as hemostatic agents, playing a critical role in promoting or accelerating blood clotting. While the term is broad, these medications are essential for stopping or preventing excessive blood loss in various clinical settings, from surgical procedures to emergency trauma situations.

In May 2023, the U.S. Food and Drug Administration (FDA) granted approval for the PerClot Absorbable Hemostatic System, introducing a plant-based hemostatic powder for surgical use. PerClot is an adjunct hemostat designed to assist surgeons in controlling bleeding that is mild to moderate when other conventional methods are ineffective or impractical.

Clinical studies have shown PuraStat achieves high rates of initial hemostasis, particularly for mild and moderate bleeding during endoscopic procedures. So, **what is PuraStat used for**? It is a versatile peptide gel primarily employed to stop bleeding in various surgical and gastrointestinal settings.